The Role of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Specimens for Next Generation Sequencing in Non-Small Cell Lung Cancer: A Clinical Perspective

Stoy S and Murgu S*
University of Chicago Medical Center, Chicago, Illinois, USA

Introduction

The National Comprehensive Cancer Network (NCCN) 2017 Clinical Practice Guidelines for Non-Small Cell Lung Cancer (NSCLC) recommend concomitant diagnosis, staging and acquisition of adequate material for genetic testing [1]. Endobronchial ultrasound (EBUS) guided transbronchial needle aspiration (TBNA) is recommended as the best first test for diagnosis and staging of lung cancer [2]. In fact, the majority of patients with lung cancer are diagnosed by small volume biopsies or cytology specimens [3] and the majority of patients are diagnosed at an advanced stage for which broad molecular profiling is recommended [1].

Next Generation Sequencing (NGS) also known as massively parallel sequencing, is a form of broad molecular profiling utilizing a single test to identify thousands of somatic or germline mutations from hundreds of genes allowing for the examination of the entire cancer genome and transcriptome [4]. NGS identifies mutations targetable with approved drugs and may detect other genetic abnormalities, which allows enrollment in clinical trials. Published evidence suggests that NGS is more sensitive than conventional testing for potentially targetable driver-mutations (e.g. EGFR, KRAS, ALK, ROS1, RET) [5,6]. Furthermore, NCCN recommendations go beyond testing for EGFR, ALK, and ROS-1. NGS uncovers mutations for which a targeted agent is available and recommended by NCCN guidelines in 26% of patients; an additional 39% of patients tested with NGS may have a genomic alterations for which a targeted agent is available on a clinical trial [6]. Comprehensive genetic profiling is also warranted at the time of disease progression to evaluate for secondary mutations, which might be targetable by approved drugs, offer prognostic value or help guide referrals towards clinical trials [1,7,8]. Mechanisms of resistance to EGFR TKIs (T790 M mutation, MET amplification, BRAF and PIK3CA mutations) can be identified and targeted [7]. Resistance mechanisms to first generation ALK inhibitors (eg. crizotinib) are increasingly discovered and may be targeted by newer ALK inhibitors which have been FDA approved (eg. ceritinib, alecitinib) [9-11]. These resistance mutations are identified by testing large gene panels made feasible by NGS [11].

While NGS testing of formalin fixed paraffin embedded (FFPE) cell block samples is feasible [12,13], the DNA quality is likely to be better on cytology smears [14-16]. Moreover, cellularity and adequacy can be assessed at the time of the procedure on slides via rapid onsite examination (ROSE), whereas cell block adequacy cannot be assessed intra-procedurally. Prior studies demonstrate the feasibility of extracting DNA from fine needle aspiration (FNA) tumor samples preserved on cytology slides [17-21] and these studies show that there is a direct correlation between slide cellularity and successful NGS testing. Slides with greater than 5000 cells or at least 5 ng/mL of DNA are successful 95% of the time for sequencing of 50 target genes [17]. Notably, studies that evaluated NGS panels with >200 genes were all performed on histology samples or cell blocks, not on smears [6,13].

In this clinical perspective, we describe our institution’s workflow for NGS testing of 50 gene (Oncoscreen) and >1000 gene (OncoPlus) panels on slide cytology samples obtained by EBUS-TBNA from metastatic mediastinal, hilar or interlobar lymph nodes in patients with NSCLC.

Specimen Acquisition, Handling and Processing

On EBUS examination, if a lymph node greater than 5mm is identified during a mediastinal staging procedure, an EBUS TBNA of the lymph node is performed using a 25-gauge needle (Figure 1). A minimum of three aspirates per node is performed during a routine EBUS-TBNA procedure. This process continues through the remaining lymph node stations. Following aspiration of a sample, the needle is removed from the scope and a drop of sample material is discharged onto a glass slide, first by advancing the needle stylet and, if insufficient material is discharged, then followed by injection of air using an empty syringe attached to the stylet hub. The material dispelled on the glass slide is then smeared with a second slide resulting in two smears. One of the slides is air-dried using Diff-Quik stain and undergoes (ROSE). The other slide is sprayed-fixed with alcohol for future Pap staining. After each pass, all remaining aspirate material from the needle is ejected

Figure 1: Image capture of a 25-gauge Endobronchial Ultrasound needle (EXPECT™ Pulmonary Needle, Boston Scientific) within an 11Rs lymph node during a TBNA procedure.
(air flushed) into Cytolyt solution or formalin, and is subsequently processed into a cell-block.

On site review of the Diff-Quik smears is performed by an attending cytopathologist (Figure 2). If the diagnosis is favored to be non-small cell lung cancer, the cytopathologist evaluates the adequacy of the smear cellularity for molecular studies. At our institution, approximately 2000 tumor cells are required for the Oncoscreen panel and 20,000 tumor cells for the OncoPlus panel. The estimation of cellularity is based on the experience of the cytopathologist. In general, if more than half of the smear has tumor then the cellularity is considered adequate for both panels. If the smear is considered sufficient for diagnosis but inadequate for molecular studies, additional passes are performed and evaluated until an adequate smear is obtained. If needed, several smears may be combined to achieve the minimum cellularity requirement.

NGS techniques

Fusion panel – the genes analyzed for fusions/translocations: ALK, RET, and ROS1. A full description is provided online (http://uchicagomedlabs.testcatalog.org/show/FUSNCS).

OncoScreen – This is a solid tumor mutation testing by NGS for 50 genes that include all targetable mutations with drugs approved by NCCN guidelines. A full description and list of covered genomic regions within these genes is provided online (http://uchicagomedlabs.testcatalog.org/show/NGFFPE-FFPE-NGSCS-Cytology-Smear--1).

OncoPlus – This is a somatic mutation testing by NGS that is designed to interrogate 1,213 cancer-related genes with a subset clinically reported for personalized care. A full description and list of covered genomic regions within these genes is provided online (http://uchicagomedlabs.testcatalog.org/show/NGPLSC).

Conclusion

For patients suffering form advanced NSCLC, currently approved drugs or those in clinical trials are increasingly targeting driver mutations. Therefore, broad molecular profiling is warranted and recommended by guidelines for personalized lung cancer treatment. EBUS-TBNA specimens may be the first and indeed the only source of lung cancer material obtained during the course of a patient's disease. It is promising that this minimally invasive procedure, which allows for immediate adequacy assessment for genetic testing via ROSE, provides samples with optimal DNA quality (e.g. cytolgy smears) that may be used for comprehensive genetic testing. This may allow individualized treatment at time of diagnosis of advanced lung cancer or disease progression without requiring more invasive procedures for tissue acquisition.

Acknowledgement

There are no conflicts of interest related to the content of this manuscript. This was was not supported by any grants or any other funds.

References

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2016) Non-small cell lung cancer. Version 3.2017.
2. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, et al. (2013) Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd edn. American College of Chest Physicians evidence-based clinical practice guidelines Chest.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2): 244-285.
4. Blumthall GM, Mansfield E, Paziur R (2016) Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol 2(1): 13-14.
5. Lim SM, Kim EY, Kim HR, Ah SM, Greenbowe JR, et al. (2016) Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget 7(17): 24172-24178.
6. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, et al. (2015) Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinoma otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21(16): 3631-3639.
7. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75): 75.
8. Novello S, Barlesi F, Caliﬀaro R, Cufer T, Ekman S, et al. (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 27: v1-v27.
9. Kim H, Chung JH (2015) Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res 4(2):149–155.
10. Bosc C, Ferretti GR, Cadranel J, Audigier-Valette C, Besse B, et al. (2015) Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol 10(2): 247-253.
11. Sullivan I and Planchard D. (2016) ALK inhibitors in non-small cell lung cancer: The latest evidence and developments. Ther Adv Med Oncol 8(1): 32–47.
12. Qiu T, Guo H, Zhao H, Wang L, Zhang Z (2015) Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by ﬁne-needle aspiration cytology. Sci Rep 11; (5):11317.
13. Young G, Wang K, He J, Otto G, Hawryluk M, et al. (2013) Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 121(12): 688-694.
14. Fischer AH, Cibas ES, Howell LP, Kurian EM, Laucirica R, et al. (2011) Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol 29(24): 3331-3332.
15. Vincenck V, Nazsiri M, Nadji M, Morales AR (2003) A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest 83(10): 1427-1435.
16. Treece AL, Montgomery ND, Patel NM, Civalier CJ, Dodd LG, et al. (2016) FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas. Cancer Cytopathol 124(6): 406-414.
17. Gleeson FC, Kipp BR, Levy MJ, Voss JS, Hampson MB, et al. (2014) Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. Cancer Cytopathol 122(11): 822-832.
18. Gleeson FC, Kipp BR, Kerr SE, Voss JS, Lazaridis KN, et al. (2015) Characterization of endoscopic ultrasound fine-needle aspiration cytology
by targeted next-generation sequencing and theranostic potential. Clin Gastroenterol Hepatol 13(1): 37-41.

19. Karnes HE, Duncavage EJ, Bernadt CT (2014) Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol 122(2): 104-113.

20. Shamanna KR, Portier BP, Singh RR, Routbort MJ, Aldape KD, et al. (2014) Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: Promises and challenges for routine clinical diagnostics. Mod Pathol 27(2): 314-327.

21. Scarpa A, Sikora K, Fassan M, Rachiglio AM, Cappellesso R, et al. (2013) Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. PLoS One 8(11): e80478.